| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9636407 | FRESENIUS KABI USA | Caspofungin acetate formulations |
Dec, 2032
(9 years from now) | |
Caspofungin Acetate is owned by Fresenius Kabi Usa.
Caspofungin Acetate contains Caspofungin Acetate.
Caspofungin Acetate has a total of 1 drug patent out of which 0 drug patents have expired.
Caspofungin Acetate was authorised for market use on 30 December, 2016.
Caspofungin Acetate is available in powder;intravenous dosage forms.
The generics of Caspofungin Acetate are possible to be released after 21 December, 2032.
Drugs and Companies using CASPOFUNGIN ACETATE ingredient
Market Authorisation Date: 30 December, 2016
Treatment: NA
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
CASPOFUNGIN ACETATE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic